Multiple Sclerosis

Serum levels of interleukin-7 and C-X-C motif chemokine ligand 10 appeared to provide the most accurate means of identifying large differences in disease risk.

According to the review, understanding the basis for the neurodegeneration of MS is the next big challenge for the treatment of the disease.

New research suggests Ocrevus saves money over subcutaneous interferon beta 1-a in the long run, though insurers say they need more data to get a clear picture of a drug’s value.

A Seattle company is hoping its technology will help drug companies more efficiently test out the safety and efficacy of drugs that must cross the blood-brain barrier.

There are currently no dietary guidelines for patients with MS and their at-risk relatives. And so far, dietary studies for MS patients have centered on vitamin D and obesity, but not overall diets.

Six years after it was initially rejected by regulators, a new relapsing remitting multiple sclerosis drug has been approved for sale in Europe.

A deal between Biogen and a large Puerto Rican pharmacy benefits manager will tie multiple sclerosis drug payments to clinical outcomes.

A group of patients following resistance training improved thier cortical thickness and MS Functional Composite score by trial's end.

Hizentra prevents neuromuscular disability and impairment relapse in patients with CIDP, a rare immune-mediated disorder of the peripheral nerves.

Though safer for relapsing-remmitting multiple sclerosis than new disease-modifying therapies, the treatment nearly doubles the chance of a patient suffering from a stroke.

MS patients were significantly outscored by a control group in a series of social interaction tests.

Allen Bowling, MD, PhD, explains the benefits and roadblocks of alternative medicine for MS.

Omitted data reveals why Lemtrada's treatment of multiple sclerosis could leave patients susceptible to secondary autoimmune conditions.

He and a Danish team believe they've found the cause of multiple sclerosis.

The Mount Sinai Hospital neurology professor shares his thoughts on MS care.

The study presented at CMSC 2017 compared the treatments to an interferon.

Stephen Krieger, MD, an associate professor at Mount Sinai Hospital, discusses the impact that recently-approved drug ocrelizumab has on the state of multiple sclerosis care, as well as his patient-centered app that depicts the MS condition in a more accurate manner, at the 2017 Consortium of Multiple Sclerosis Centers in New Orleans.

Allen Bowling, MD, PhD, physician associate of the Colorado Neurological Institute, discussed widely-researched benefits of cannabis on MS effects, its shortcomings, and the broad outcomes of alternative treatment.

Clyde Markowitz, MD, director of the MS Center at the University of Pennsylvania, discusses how the patterns of male-to-female ratio in MS diagnoses may be linked to hormones, and whether testosterone could be key in bettering treatment.

It took 5 visits to the doctor to correctly diagnose many MS patients.

Smokers found to have altered levels of MAIT than the general population.